Bioactivity:Lanraplenib is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding t
CAS Nr:
1800046-95-0
Purity: 
98%
SMILES: 
C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N
Formula: 
C23H25N9O
Molecular weight: 
443,5
Pathway: 
Angiogenesis,Tyrosine Kinase/Adaptors
Target: 
Syk,Syk